Collectively, we provide detailed insights into MØ-specific IFNγ-activated transcriptional changes, mediated by STAT1-PU.1 co-binding and associated epigenetic changes, and offer the identification of new biomarkers and therapeutic targets in atherosclerosis. This evidence concerns the gene STAT1 and atherosclerosis.